|
Apr 1
|
Biora Therapeutics Announces $6 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
|
|
Mar 27
|
BIOR: Negotiations Accelerating
|
|
Mar 27
|
Biora Therapeutics, Inc. (NASDAQ:BIOR) Q4 2023 Earnings Call Transcript
|
|
Mar 27
|
Q4 2023 Biora Therapeutics Inc Earnings Call
|
|
Mar 26
|
Biora Therapeutics Provides Corporate Update and Reports Fourth Quarter and Full-Year 2023 Financial Results
|
|
Mar 18
|
Biora Therapeutics to Report Fourth Quarter and Full Year 2023 Financial Results and Provide Corporate Update
|
|
Mar 11
|
Biora Therapeutics Further Reduces Net Debt and Monetizes Legacy Asset
|
|
Jan 16
|
Biora Therapeutics Provides Outlook for 2024
|
|
Dec 20
|
BIOR: Capitalizing on Progress: BT-600 to Start
|
|
Dec 19
|
Biora Therapeutics Announces New Patent for its NaviCap™ Targeted Oral Delivery Platform
|
|
Dec 18
|
Biora Therapeutics Accelerates Debt Reduction and Raises Capital with Large Institutional Investors
|
|
Nov 30
|
Biora Therapeutics Announces FDA Clearance of IND Application for Drug/Device Combination BT-600 Targeting Treatment of Ulcerative Colitis
|